Genenta Science Receives Nasdaq Minimum Bid Price Deficiency Notice

• Genenta Science received a Nasdaq deficiency notice on October 16, 2026, for failing the $1.00 minimum bid price requirement.
• American Depositary Shares (ADSs) traded below $1.00 for 30 consecutive business days, September 3–October 15, 2026; trading continues without immediate delisting.
• The initial 180-calendar-day compliance period ends April 14, 2027; ADSs must close at $1.00 or higher for at least 10 consecutive business days.
• An additional 180-calendar-day extension may be available, subject to meeting other listing standards and providing written notice of plans to cure the deficiency.
• Shareholders have authorized a reverse stock split ranging from 1-for-10 to 1-for-20, which the board may implement to address the deficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genenta Science S.p.A. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610211601PRIMZONEFULLFEED1001279202) on October 21, 2026, and is solely responsible for the information contained therein.